Vivo Capital LLC Boosts Position in Rezolute, Inc. (NASDAQ:RZLT)

Vivo Capital LLC grew its holdings in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 569.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,242,842 shares of the company's stock after purchasing an additional 2,758,403 shares during the period. Vivo Capital LLC owned approximately 8.18% of Rezolute worth $3,219,000 at the end of the most recent quarter.

Separately, Federated Hermes Inc. lifted its holdings in shares of Rezolute by 53.6% in the fourth quarter. Federated Hermes Inc. now owns 10,154,327 shares of the company's stock worth $10,083,000 after buying an additional 3,544,053 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RZLT has been the topic of a number of analyst reports. Jonestrading began coverage on shares of Rezolute in a report on Thursday, April 18th. They set a "buy" rating and a $10.00 target price on the stock. JMP Securities reiterated a "market outperform" rating and issued a $7.00 price objective on shares of Rezolute in a research report on Thursday, April 18th. Maxim Group assumed coverage on Rezolute in a research report on Tuesday, April 9th. They set a "buy" rating and a $8.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of Rezolute in a report on Thursday, March 7th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $8.80.

Rezolute Stock Down 2.4 %

Shares of RZLT traded down $0.07 during trading hours on Thursday, hitting $2.85. The company had a trading volume of 162,062 shares, compared to its average volume of 302,423. The firm has a market cap of $114.36 million, a P/E ratio of -2.59 and a beta of 1.29. Rezolute, Inc. has a 52-week low of $0.72 and a 52-week high of $3.69. The stock's 50 day moving average price is $2.44 and its 200 day moving average price is $1.51.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Tuesday, February 13th. The company reported ($0.27) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.27). On average, research analysts expect that Rezolute, Inc. will post -1.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Daron Evans acquired 50,000 shares of the stock in a transaction dated Friday, March 8th. The stock was purchased at an average cost of $1.93 per share, with a total value of $96,500.00. Following the completion of the purchase, the chief financial officer now owns 120,900 shares in the company, valued at approximately $233,337. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In other Rezolute news, CFO Daron Evans purchased 50,000 shares of Rezolute stock in a transaction that occurred on Friday, March 8th. The shares were bought at an average price of $1.93 per share, for a total transaction of $96,500.00. Following the acquisition, the chief financial officer now directly owns 120,900 shares in the company, valued at $233,337. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Young-Jin Kim acquired 36,503 shares of the company's stock in a transaction on Thursday, March 7th. The stock was acquired at an average price of $1.91 per share, with a total value of $69,720.73. Following the acquisition, the director now owns 115,450 shares in the company, valued at approximately $220,509.50. The disclosure for this purchase can be found here. Insiders have bought a total of 179,403 shares of company stock valued at $306,601 in the last quarter. Insiders own 20.80% of the company's stock.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.